Quality of Reporting of Serious Adverse Drug Events to an Institutional Review Board: A Case Study with the Novel Cancer Agent, Imatinib Mesylate-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Quality of Reporting of Serious Adverse Drug Events to an Institutional Review Board: A Case Study with the Novel Cancer Agent, Imatinib Mesylate

Published:2009-05-19 Issue:11 Volume:15 Page:3850-3855
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Dorr David A.,Burdon Rachel,West Dennis P.,Lagman Jennifer,Georgopoulos Christina,Belknap Steven M.,McKoy June M.,Djulbegovic Benjamin,Edwards Beatrice J.,Weitzman Sigmund A.,Boyle Simone,Tallman Martin S.,Talpaz Moshe,Sartor Oliver,Bennett Charles L.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug-Induced/Iatrogenic Respiratory Disease: With Emphasis on Unusual, Rare, and Emergent Drug-Induced Reactions;Orphan Lung Diseases;2023

2. Systemic Barriers and Potential Concerns from Reporting Serious Adverse Drug Reactions;Cancer Drug Safety and Public Health Policy;2022

3. Effect of adalimumab interventions on general infection among adults: a systematic review and meta-analysis of randomized controlled trials;Expert Review of Anti-infective Therapy;2021-04-13

4. The quality of reporting general safety parameters and immune-related adverse events in clinical trials of FDA-approved immune checkpoint inhibitors;BMC Cancer;2020-11-23

5. Inferences About Drug Safety in Phase III Trials in Oncology: Examples From Advanced Prostate Cancer;JNCI: Journal of the National Cancer Institute;2020-08-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP